UBE2C and breast carcinoma: So the aim of this study was (1) to determine the prognostic power of UBE2C by means of IHC staining in 92 N+ breast cancer patients; (2) to compare the power of this proliferation marker with that of the reference marker in breast cancer, Ki-67, and (3) to evaluate if UBE2C added predictive accuracy to that provided by the combined prognostic index: Nottingham Prognostic Index (NPI) (Stuart-Harris et al, 2008).